GlobeNewswire·Nov 12, 2026, 8:45 AM ET

Alps Group Inc Launches Pharmaco-Interaction (PCI) Unit via MyGenome, Debuting with CYP450 Drug Interaction Testing

Alps Group Inc (Nasdaq: ALPS) launched its Pharmaco-Interaction (PCI) laboratory unit within its MyGenome subsidiary in Kuala Lumpur, Malaysia.
The PCI unit's first commercial service is CYP450 inhibitory IC50 testing across seven major enzyme isoforms (CYP3A4, CYP2D6, CYP2C9, CYP1A2, CYP2C19, CYP2B6, & CYP2E1).
These seven isoforms metabolize approximately 90% of marketed clinical drugs to support regulatory compliance & safe product use.
FDA & EMA guidelines recommend CYP inhibition evaluation for clinical & botanical drugs, a standard PCI aims to make accessible to manufacturers & researchers.
Target clients for PCI services include herbal & supplement manufacturers, pharmaceutical companies, & research institutions.
The unit utilizes LC-MS/MS Triple Quadrupole technology for its testing procedures.
Dr. Tham Seng Kong, Group CEO, stated the launch addresses limited access to accredited CYP inhibition testing in Southeast Asia.
Professor Nik Soriani, PCI Scientific Lead, emphasized that the service counters the misconception that natural products are inherently safe with prescription drugs.
PCI joins Alps' expanding portfolio of high-value B2B services in precision oncology, genomics, & translational research.
Alps Group Inc operates as a revenue-generating integrated biotechnology platform headquartered in Malaysia, focusing on cell manufacturing, molecular diagnostics, & clinical delivery.